{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:01:12Z","timestamp":1792144872052,"version":"4.4.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2022NSFSC1415"],"award-info":[{"award-number":["2022NSFSC1415"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016350","name":"Sichuan Provincial Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["25MSZX482"],"award-info":[{"award-number":["25MSZX482"]}],"id":[{"id":"10.13039\/501100016350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.virusres.2025.199655","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T23:03:28Z","timestamp":1762038208000},"page":"199655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Antineoplastic agents-associated hepatitis B virus reactivation: Research progress and molecular mechanisms"],"prefix":"10.1016","volume":"361","author":[{"given":"Huajie","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlin","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-9256","authenticated-orcid":false,"given":"Kai","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2025.199655_bib0001","unstructured":"Ahmadzadeh M., Johnson La Fau - Heemskerk B., Heemskerk B Fau - Wunderlich J.R., Wunderlich Jr Fau - Dudley ME, Dudley Me Fau - White DE, White De Fau - Rosenberg SA, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired 2025."},{"key":"10.1016\/j.virusres.2025.199655_bib0002","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2020004907","article-title":"Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy","volume":"136","author":"Cao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.virusres.2025.199655_bib0003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.virusres.2025.199655_bib0004","article-title":"Hepatitis B virus reactivation associated with therapeutic interventions","volume":"8","author":"Chang","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.virusres.2025.199655_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.770124","article-title":"Hepatitis B virus reactivation associated with therapeutic interventions","volume":"8","author":"Chang","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.virusres.2025.199655_bib0006","doi-asserted-by":"crossref","first-page":"457","DOI":"10.14218\/JCTH.2023.00537","article-title":"Paclitaxel-induced immune dysfunction and activation of transcription factor AP-1 facilitate Hepatitis B virus replication","volume":"12","author":"Chen","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0007","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.freeradbiomed.2018.12.008","article-title":"Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS\/JNK and inhibition of the akt\/mTOR pathway","volume":"131","author":"Chen","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.virusres.2025.199655_bib0008","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","article-title":"Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma","volume":"37","author":"Cheng","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2025.199655_bib0009","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1751-2980.12848","article-title":"Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis","volume":"21","author":"Cheung","year":"2020","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.virusres.2025.199655_bib0010","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.ijrobp.2008.12.072","article-title":"Synergistic effect of radiation and interleukin-6 on hepatitis B virus reactivation in liver through STAT3 signaling pathway","volume":"75","author":"Chou","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.virusres.2025.199655_bib0011","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0012","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.virusres.2025.199655_bib0014","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00432-022-04133-8","article-title":"Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis","volume":"149","author":"Ding","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.virusres.2025.199655_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0493-9","article-title":"\u03b1-PD-1 therapy elevates Treg\/Th balance and increases tumor cell pSmad3 that are both targeted by \u03b1-tgf\u03b2 antibody to promote durable rejection and immunity in squamous cell carcinomas","volume":"7","author":"Dodagatta-Marri","year":"2019","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.virusres.2025.199655_bib0016","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/QAD.0b013e328334bddb","article-title":"Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption","volume":"24","author":"Dore","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.virusres.2025.199655_bib0017","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic Hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2025.199655_bib0018","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S2468-1253(24)00089-X","article-title":"WHO 2024 hepatitis B guidelines: an opportunity to transform care","volume":"9","author":"Easterbrook","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0019","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2025.199655_bib0020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0021","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.cgh.2023.02.032","article-title":"New perspectives on development of curative strategies for chronic Hepatitis B","volume":"21","author":"Feld","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0022","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1172\/JCI36604","article-title":"PD-L1 negatively regulates CD4+CD25+Foxp3+ tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV","volume":"119","author":"Franceschini","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.virusres.2025.199655_bib0023","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0024","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2020.08.041","article-title":"Hepatitis B reactivation and immune check point inhibitors","volume":"53","author":"Godbert","year":"2021","journal-title":"Dig. Liver. Dis."},{"key":"10.1016\/j.virusres.2025.199655_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/v16040609","article-title":"Mechanisms of Hepatitis B Virus cccDNA and minichromosome formation and HBV gene transcription","volume":"16","author":"G\u00f3mez-Moreno","year":"2024","journal-title":"Viruses."},{"key":"10.1016\/j.virusres.2025.199655_bib0026","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.virusres.2025.199655_bib0027","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis","author":"Haanen","year":"2025","journal-title":"Treat. Follow-Up"},{"key":"10.1016\/j.virusres.2025.199655_bib0028","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00262-021-02911-w","article-title":"Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis","volume":"70","author":"He","year":"2021","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.virusres.2025.199655_bib0029","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/451694","article-title":"The PD-1\/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion","volume":"2011","author":"Hofmeyer","year":"2011","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.virusres.2025.199655_bib0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection","volume":"11","author":"Hoogeveen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virusres.2025.199655_bib0031","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/17474124.2020.1774364","article-title":"Hepatitis B reactivation: diagnosis and management","volume":"14","author":"Huang","year":"2020","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0032","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.virusres.2025.199655_bib0033","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","article-title":"A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization","volume":"43","author":"Jang","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2025.199655_bib0034","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3851\/IMP1840","article-title":"Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma","volume":"16","author":"Jang","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virusres.2025.199655_bib0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.virusres.2025.199655_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103617","article-title":"Targeting hepatitis B virus cccDNA levels: recent progress in seeking small molecule drug candidates","volume":"28","author":"Jin","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.virusres.2025.199655_bib0037","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"key":"10.1016\/j.virusres.2025.199655_bib0038","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/j.gastro.2013.12.036","article-title":"Hepatic immune regulation and its involvement in viral hepatitis infection","volume":"146","author":"Knolle","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2025.199655_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/v11110997","article-title":"ATM and ATR expression potentiates HBV replication and contributes to reactivation of HBV infection upon DNA damage","volume":"11","author":"Kostyusheva","year":"2019","journal-title":"Viruses."},{"key":"10.1016\/j.virusres.2025.199655_bib0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12072-018-9912-8","article-title":"Immunological cure of HBV infection","volume":"13","author":"Lang","year":"2019","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.virusres.2025.199655_bib0041","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2217\/fon-2020-1196","article-title":"Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons?","volume":"17","author":"Lasagna","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.virusres.2025.199655_bib0042","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.virusres.2025.199655_bib0043","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1053\/gast.2002.31887","article-title":"Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen","volume":"122","author":"Lau","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2025.199655_bib0044","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejca.2020.02.026","article-title":"Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection","volume":"130","author":"Lee","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.virusres.2025.199655_bib0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12072-022-10450-4","article-title":"Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors","volume":"17","author":"Lei","year":"2023","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.virusres.2025.199655_bib0046","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3389\/fimmu.2020.01037","article-title":"Anti-PD-1\/PD-L1 blockade immunotherapy employed in treating Hepatitis B virus infection-related advanced hepatocellular carcinoma: a literature review","volume":"11","author":"Li","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virusres.2025.199655_bib0047","article-title":"Risk of HBV reactivation in patients with resolved HBV infection receiving anti-CD19 chimeric antigen receptor T cell therapy without antiviral prophylaxis","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virusres.2025.199655_bib0048","first-page":"3496","article-title":"Cisplatin enhances Hepatitis B Virus replication and PGC-1alpha expression through","volume":"8","author":"Li","year":"2018","journal-title":"Endoplasmic Reticulum Stress. Sci. Rep."},{"key":"10.1016\/j.virusres.2025.199655_bib0049","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0050","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2025.199655_bib0051","first-page":"1221","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science 1979"},{"key":"10.1016\/j.virusres.2025.199655_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01360-21","article-title":"Proteomic analysis of nuclear Hepatitis B virus relaxed circular DNA-associated proteins identifies UV-damaged DNA binding protein as a host factor involved in covalently closed circular DNA formation","volume":"96","author":"Marchetti","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2025.199655_bib0053","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-015-0284-z","article-title":"Immunological consequences of JAK inhibition: friend or foe?","volume":"10","author":"McLornan","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.virusres.2025.199655_bib0054","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1172\/JCI116950","article-title":"Hepatitis B virus persistence after recovery from acute viral hepatitis","volume":"93","author":"Michalak","year":"1994","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.virusres.2025.199655_bib0055","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis","volume":"22","author":"Mozessohn","year":"2015","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.virusres.2025.199655_bib0056","doi-asserted-by":"crossref","first-page":"111","DOI":"10.36401\/JIPO-23-28","article-title":"Management of Hepatitis B Virus and Hepatitis C Virus infections in patients with cancer receiving immune checkpoint inhibitors","volume":"7","author":"Mustafayev","year":"2024","journal-title":"J. ImmunOther Precis. Oncol."},{"key":"10.1016\/j.virusres.2025.199655_bib0057","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of Hepatitis B Virus: a review of clinical guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clin. Liver. Dis."},{"key":"10.1016\/j.virusres.2025.199655_bib0058","doi-asserted-by":"crossref","first-page":"21455","DOI":"10.3390\/ijms151121455","article-title":"Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment","volume":"15","author":"Nakamoto","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virusres.2025.199655_bib0059","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/jvi.69.6.3350-3357.1995","article-title":"The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes","volume":"69","author":"Newbold","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2025.199655_bib0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist."},{"key":"10.1016\/j.virusres.2025.199655_bib0061","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/14740338.2023.2181339","article-title":"Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature","volume":"22","author":"Pan","year":"2023","journal-title":"Expert. Opin. Drug Saf."},{"key":"10.1016\/j.virusres.2025.199655_bib0062","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/hep.32241","article-title":"Risk of HBV reactivation during therapies for HCC: a systematic review","volume":"75","author":"Papatheodoridi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2025.199655_bib0063","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0064","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2016.0024","article-title":"Prevention of Hepatitis B reactivation in the setting of immunosuppression","volume":"22","author":"Pattullo","year":"2016","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0065","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0066","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Polaris Observatory C","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0067","first-page":"600","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science 1979"},{"key":"10.1016\/j.virusres.2025.199655_bib0068","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2025.199655_bib0069","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T\u2013lymphocyte response","volume":"2","author":"Rehermann","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.virusres.2025.199655_bib0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.virusres.2025.199655_bib0071","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0072","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.virusres.2025.199655_bib0073","unstructured":"Schneider B.A.-.O., Naidoo J.A.-.O., Santomasso B.D., Lacchetti C.A.-.O.X., Adkins S.A.-.O.X., Anadkat M., Atkins M.A.-.O., Brassil K.A.-.O., Caterino J.M., Chau I.A.-.O., Davies M.A.-.O.X., Ernstoff M.A.-.O., Fecher L.A.-.O., Ghosh M.A.-.O., Jaiyesimi I., Mammen J.A.-.O.X., Naing A.A.-.O., Nastoupil L.J., Phillips T., Porter L.A.-.O., Reichner C.A., Seigel C., Song J.M., Spira A.A.-.O., Suarez-Almazor M.A.-.O., Swami U.A.-.O., Thompson J.A., Vikas P.A.-.O., Wang Y.A.-.O., Weber J.A.-.O., Funchain P.A.-.O., Bollin K.A.-.O. 2025. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update."},{"key":"10.1016\/j.virusres.2025.199655_bib0074","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.virusres.2025.199655_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1179689","article-title":"HBV reactivation and its effect on survival in HBV-related hepatocarcinoma patients undergoing transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors","volume":"13","author":"Shen","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.virusres.2025.199655_bib0076","doi-asserted-by":"crossref","first-page":"m2200","DOI":"10.1136\/bmj.m2200","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.virusres.2025.199655_bib0077","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.virusres.2025.199655_bib0078","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin. Liver. Dis."},{"key":"10.1016\/j.virusres.2025.199655_bib0079","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.virusres.2025.199655_bib0080","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41423-020-00556-w","article-title":"Implications of metabolism-driven myeloid dysfunctions in cancer therapy","volume":"18","author":"Strauss","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.virusres.2025.199655_bib0081","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.virusres.2025.199655_bib0082","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00228-018-2487-4","article-title":"Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis","volume":"74","author":"Su","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.virusres.2025.199655_bib107","article-title":"Rosmarinic acid and dengue virus: Computational insights into antiviral potential","volume":"2","author":"Sugumar","year":"2025","journal-title":"LabMed Discovery"},{"key":"10.1016\/j.virusres.2025.199655_bib0083","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/hep.24529","article-title":"Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy","volume":"54","author":"Teng","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2025.199655_bib0084","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2025.199655_bib0085","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/acsinfecdis.0c00638","article-title":"HBsAg, subviral particles, and their clearance in establishing a functional cure of chronic Hepatitis B Virus infection","volume":"7","author":"Vaillant","year":"2020","journal-title":"ACS. Infect. Dis."},{"key":"10.1016\/j.virusres.2025.199655_bib0086","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3324\/haematol.2018.210252","article-title":"Reactivation of hepatitis B virus infection in patients with hematologic disorders","volume":"104","author":"Wang","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.virusres.2025.199655_bib0087","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/cam4.1468","article-title":"RFX1 participates in doxorubicin-induced hepatitis B virus reactivation","volume":"7","author":"Wang","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.virusres.2025.199655_bib0088","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00432-024-05677-7","article-title":"Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era","volume":"150","author":"Wang","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.virusres.2025.199655_bib0089","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1038\/s41375-020-0936-4","article-title":"Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.virusres.2025.199655_bib0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2019.05.001","article-title":"Hepatitis B reactivation during treatment of tyrosine kinase inhibitors-experience in 142 adult patients with chronic myeloid leukemia","volume":"81","author":"Wang","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.virusres.2025.199655_bib0091","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1016\/j.vaccine.2009.06.027","article-title":"Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C","volume":"27","author":"Wedemeyer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2025.199655_bib0092","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2025.199655_bib0093","unstructured":"Wong G.L.H., Gane E., Lok A.S.F. 2025. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?"},{"key":"10.1016\/j.virusres.2025.199655_bib0094","article-title":"Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: a systematic review and meta-analysis","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.virusres.2025.199655_bib0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virusres.2025.199655_bib0096","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40249-023-01128-6","article-title":"Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Xia","year":"2023","journal-title":"Infect. Dis. Poverty."},{"key":"10.1016\/j.virusres.2025.199655_bib0097","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1038\/s41375-020-0913-y","article-title":"Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection","volume":"34","author":"Yang","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.virusres.2025.199655_bib0098","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2022.10.008","article-title":"Current best practice in Hepatitis B management and understanding long-term prospects for cure","volume":"164","author":"Yardeni","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virusres.2025.199655_bib0099","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2020.01.027","article-title":"Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection","volume":"73","author":"Yeh","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virusres.2025.199655_bib0100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.virusres.2025.199655_bib0101","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.virusres.2025.199655_bib0102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004196","article-title":"Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: a systematic review and meta-analysis","volume":"20","author":"Yin","year":"2023","journal-title":"PLoS. Med."},{"key":"10.1016\/j.virusres.2025.199655_bib0103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1330644","article-title":"The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy","volume":"15","author":"Zeng","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virusres.2025.199655_bib0104","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.antiviral.2015.10.009","article-title":"Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: search for the \"magic bullet\" to kill cccDNA","volume":"123","author":"Zhang","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virusres.2025.199655_bib0105","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.7150\/jca.77247","article-title":"Hepatitis B virus reactivation in cancer patients undergoing immune checkpoint inhibitors therapy: a systematic review","volume":"13","author":"Zhao","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.virusres.2025.199655_bib0106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000943","article-title":"Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy","volume":"8","author":"Ziogas","year":"2020","journal-title":"J. ImmunOther Cancer"}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170225001339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170225001339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:04:38Z","timestamp":1766055878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170225001339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":107,"alternative-id":["S0168170225001339"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2025.199655","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antineoplastic agents-associated hepatitis B virus reactivation: Research progress and molecular mechanisms","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2025.199655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199655"}}